This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jan;19(1):217-8.

doi: 10.1002/ibd.23015.

Adalimumab for ulcerative colitis: ultra or just mediocre

David Hudesman¹

Affiliations

PMID: 23292352
DOI: 10.1002/ibd.23015

Comment

Adalimumab for ulcerative colitis: ultra or just mediocre

David Hudesman. Inflamm Bowel Dis. 2013 Jan.

. 2013 Jan;19(1):217-8.

doi: 10.1002/ibd.23015.

Author

David Hudesman¹

Affiliation

¹ Beth Israel Medical Center, New York, New York, USA.

PMID: 23292352
DOI: 10.1002/ibd.23015

No abstract available

PubMed Disclaimer

Comment on

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. Sandborn WJ, et al. Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032. Epub 2011 Nov 4. Gastroenterology. 2012. PMID: 22062358 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.